Previous 10 | Next 10 |
Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...
The healthcare stocks in the S&P 500 with a ~2.5% gain outperformed all other sectors in the broader index thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%. Am...
NEW YORK, NY / ACCESSWIRE / December 18, 2021 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to Pfizer Inc. for $100.00 per share in cash is fair to Arena shareholders. Halper Sadeh encourages Arena share...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks ended the week on a down note after the simultaneous expiration of single-stock options, single-stock futures, and stock-index options, and stock-fu...
NEW YORK, NY / ACCESSWIRE / December 16, 2021 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to Pfizer Inc. for $100.00 per share in cash is fair to Arena shareholders. Halper Sadeh encourages Arena share...
Arena Pharmaceuticals got acquired by Pfizer for US$ 6.7 Bn (~100% valuation) on December 12th. As a result, the market for late-stage oral IBD candidates that big pharma can acquire is thinning. After the JAKi's black-box warning and a wave of biosimilar/generics soon entering, big p...
On a weak day for the overall equity market, COVID vaccine makers presented a bright spot on Monday. New data showing potential against the Omicron variant gave strength to Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA), Johnson & Johnson (NYSE:JNJ) and Novavax (NASDAQ:N...
Shares of Arena Pharmaceuticals (NASDAQ: ARNA) soared 80% on Monday after the drugmaker struck a merger agreement with Pfizer (NYSE: PFE) . Arena is a clinical-stage company focused on developing treatments for immuno-inflammatory conditions. It has a promising pipel...
Pfizer Inc ( NYSE: PFE ) executed a definitive agreement with Arena Pharmaceuticals ( Nasdaq: ARNA ), under which Pfizer Inc will acquire Arena Pharmaceutical for a total equity value of around $6.7 billion. Arena went up 90% after this announcement. Arena Pharmaceut...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AMC Entertainment (NYSE: AMC ) and GameStop (NYSE: GME ) are taking a beating today and traders of the meme stocks are reacting on social media. Source: Tero Vesalainen / Shutterstock.com AMC stock is co...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...